- Home
- MBC vs VERA Comparison
MBC vs VERA Comparison
Compare MBC & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBC
- VERA
- Stock Information
- Founded
- MBC 1954
- VERA 2016
- Country
- MBC United States
- VERA United States
- Employees
- MBC N/A
- VERA N/A
- Industry
- MBC Agricultural Chemicals
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- MBC Industrials
- VERA Health Care
- Exchange
- MBC Nasdaq
- VERA Nasdaq
- Market Cap
- MBC 1.5B
- VERA 1.6B
- IPO Year
- MBC N/A
- VERA 2021
- Fundamental
- Price
- MBC $11.11
- VERA $21.33
- Analyst Decision
- MBC Strong Buy
- VERA Strong Buy
- Analyst Count
- MBC 1
- VERA 9
- Target Price
- MBC $15.00
- VERA $64.44
- AVG Volume (30 Days)
- MBC 1.2M
- VERA 1.2M
- Earning Date
- MBC 05-06-2025
- VERA 05-06-2025
- Dividend Yield
- MBC N/A
- VERA N/A
- EPS Growth
- MBC N/A
- VERA N/A
- EPS
- MBC 0.77
- VERA N/A
- Revenue
- MBC $2,722,600,000.00
- VERA N/A
- Revenue This Year
- MBC $2.24
- VERA N/A
- Revenue Next Year
- MBC $3.69
- VERA N/A
- P/E Ratio
- MBC $14.39
- VERA N/A
- Revenue Growth
- MBC 1.30
- VERA N/A
- 52 Week Low
- MBC $10.07
- VERA $18.53
- 52 Week High
- MBC $20.67
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- MBC 45.04
- VERA 41.79
- Support Level
- MBC $9.78
- VERA $20.80
- Resistance Level
- MBC $11.45
- VERA $23.18
- Average True Range (ATR)
- MBC 0.50
- VERA 1.35
- MACD
- MBC 0.00
- VERA -0.08
- Stochastic Oscillator
- MBC 48.36
- VERA 10.53
About MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.